Dr. Amirhossein Sahebkar received his PharmD and PhD (in Medical Biotechnology) degrees from the Mashhad University of Medical Sciences (MUMS; Mashhad, Iran). His research focuses on the investigation of novel natural products for the management of severe cardiometabolic disorders. He has conducted numerous research projects dealing with basic, experimental, and clinical research on curcuminoids. Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing.

• Part-A: Curcumin: Introduction, structure, and physicochemical attributes1. Curcumin: historical background, introduction, structure, and physicochemical attributes2. Curcumin as a pharmaceutical leader3. Chemical structure and molecular targets of curcumin for cancer therapy4. Structural features of curcumin and its effects on cancer-related signaling pathways5. An overview of cellular, molecular, and biological aspect(s) of curcumin in cancerPart-B: Smart drug delivery approaches for curcumin delivery in cancer therapy6. Curcumin-drug conjugate-based drug delivery as cancer therapeutics7. Curcumin microcapsule-based drug delivery as cancer therapeuticsPart-C: Recent advances and regulatory aspects of gold nanoparticles8. Nanoemulsion-based curcumin delivery systems as cancer therapeutics9. Micelle-based curcumin delivery systems as cancer therapeutics10. Liposome-based curcumin delivery systems as cancer therapeutics11. Inorganic nanoparticle-based curcumin delivery as cancer therapeutics12. PLGA nanoparticle-based curcumin delivery as cancer therapeutics13. Polymersomes-based curcumin delivery as cancer therapeuticsPart-D: Recent advances in nanocurcumin delivery in cancer therapy14. Biopolymer-based formulations for curcumin delivery toward cancer management15. Nanohybrid drug delivery approach as a novel opportunity for curcumin delivery in cancer16. Codelivery of curcumin and siRNA as anticancer therapeuticsPart-E: Challenges and future perspectives of nano-curcumin drug delivery17. Challenges associated with nanocurcumin anticancer drug delivery systems18. Curcumin-loaded nanoparticles used for in vivo cancer models: an approach about their physicochemical properties and mechanism of action19. Clinical trials, patents, and marketed products of nanocurcumin-based anticancer drug delivery systems

Dr. Amirhossein Sahebkar received his PharmD and PhD (in Medical Biotechnology) degrees from the Mashhad University of Medical Sciences (MUMS; Mashhad, Iran). His research focuses on the investigation of novel natural products for the management of severe cardiometabolic disorders. He has conducted numerous research projects dealing with basic, experimental, and clinical research on curcuminoids. Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing.

• Part-A: Curcumin: Introduction, structure, and physicochemical attributes1. Curcumin: historical background, introduction, structure, and physicochemical attributes2. Curcumin as a pharmaceutical leader3. Chemical structure and molecular targets of curcumin for cancer therapy4. Structural features of curcumin and its effects on cancer-related signaling pathways5. An overview of cellular, molecular, and biological aspect(s) of curcumin in cancerPart-B: Smart drug delivery approaches for curcumin delivery in cancer therapy6. Curcumin-drug conjugate-based drug delivery as cancer therapeutics7. Curcumin microcapsule-based drug delivery as cancer therapeuticsPart-C: Recent advances and regulatory aspects of gold nanoparticles8. Nanoemulsion-based curcumin delivery systems as cancer therapeutics9. Micelle-based curcumin delivery systems as cancer therapeutics10. Liposome-based curcumin delivery systems as cancer therapeutics11. Inorganic nanoparticle-based curcumin delivery as cancer therapeutics12. PLGA nanoparticle-based curcumin delivery as cancer therapeutics13. Polymersomes-based curcumin delivery as cancer therapeuticsPart-D: Recent advances in nanocurcumin delivery in cancer therapy14. Biopolymer-based formulations for curcumin delivery toward cancer management15. Nanohybrid drug delivery approach as a novel opportunity for curcumin delivery in cancer16. Codelivery of curcumin and siRNA as anticancer therapeuticsPart-E: Challenges and future perspectives of nano-curcumin drug delivery17. Challenges associated with nanocurcumin anticancer drug delivery systems18. Curcumin-loaded nanoparticles used for in vivo cancer models: an approach about their physicochemical properties and mechanism of action19. Clinical trials, patents, and marketed products of nanocurcumin-based anticancer drug delivery systems

Dr. Amirhossein Sahebkar received his PharmD and PhD (in Medical Biotechnology) degrees from the Mashhad University of Medical Sciences (MUMS; Mashhad, Iran). His research focuses on the investigation of novel natural products for the management of severe cardiometabolic disorders. He has conducted numerous research projects dealing with basic, experimental, and clinical research on curcuminoids. Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing.

• Part-A: Curcumin: Introduction, structure, and physicochemical attributes1. Curcumin: historical background, introduction, structure, and physicochemical attributes2. Curcumin as a pharmaceutical leader3. Chemical structure and molecular targets of curcumin for cancer therapy4. Structural features of curcumin and its effects on cancer-related signaling pathways5. An overview of cellular, molecular, and biological aspect(s) of curcumin in cancerPart-B: Smart drug delivery approaches for curcumin delivery in cancer therapy6. Curcumin-drug conjugate-based drug delivery as cancer therapeutics7. Curcumin microcapsule-based drug delivery as cancer therapeuticsPart-C: Recent advances and regulatory aspects of gold nanoparticles8. Nanoemulsion-based curcumin delivery systems as cancer therapeutics9. Micelle-based curcumin delivery systems as cancer therapeutics10. Liposome-based curcumin delivery systems as cancer therapeutics11. Inorganic nanoparticle-based curcumin delivery as cancer therapeutics12. PLGA nanoparticle-based curcumin delivery as cancer therapeutics13. Polymersomes-based curcumin delivery as cancer therapeuticsPart-D: Recent advances in nanocurcumin delivery in cancer therapy14. Biopolymer-based formulations for curcumin delivery toward cancer management15. Nanohybrid drug delivery approach as a novel opportunity for curcumin delivery in cancer16. Codelivery of curcumin and siRNA as anticancer therapeuticsPart-E: Challenges and future perspectives of nano-curcumin drug delivery17. Challenges associated with nanocurcumin anticancer drug delivery systems18. Curcumin-loaded nanoparticles used for in vivo cancer models: an approach about their physicochemical properties and mechanism of action19. Clinical trials, patents, and marketed products of nanocurcumin-based anticancer drug delivery systems